BIOPHTA has developed a 7-day continuous microdosing pharmaceutical platform that utilizes self-administered dry mini-tablets that transform into a gel upon contact with the eye, providing controlled drug release. This technology addresses the low absorption rates of traditional eye drops and the discomfort of intraocular injections, significantly improving treatment adherence for patients with chronic eye conditions.
Funding
$7.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
GCUIFounders
Product
Problem
Current ophthalmic treatments, such as eye drops and injections, suffer from low drug absorption and patient non-adherence, leading to ineffective treatment of both front-of-the-eye and retinal diseases. Eye drops have poor drug absorption rates, requiring frequent applications, while injections are invasive and cause patient stress. This results in a significant unmet medical need, with millions facing vision loss despite available medications.
Solution
BIOPHTA offers a 7-day continuous microdosing pharmaceutical platform that improves the efficacy of eye treatments. The platform utilizes self-administered dry mini-tablets that transform into a gel upon contact with the eye, adhering firmly to the eye surface. This non-invasive ocular insert provides a controlled, low-dose drug release over seven days, improving treatment adherence and drug absorption compared to traditional eye drops. This approach aims to address both front-of-the-eye and retinal diseases, reducing the need for invasive injections and improving patient compliance.
Target Audience
The primary target audience includes patients with chronic eye conditions such as glaucoma, AMD (age-related macular degeneration), and DME (diabetic macular edema), as well as ophthalmologists and optometrists seeking to improve treatment adherence and efficacy.
Features
- Self-administered dry mini-tablets that transform into a gel upon contact with the eye
- Continuous microdosing for 7 days, ensuring consistent drug release
- Non-invasive ocular insert that adheres firmly to the eye surface
- Improved drug absorption compared to traditional eye drops
- Controlled, low-dose drug release, minimizing side effects